Humana Inc. (HUM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2026, filed Apr 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HUM SEC filings page.
Humana Inc. (HUM) reported $137.2B in revenue over the twelve months to Mar 31, 2026, up 14.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Humana's dominant mechanic is revenue expansion being absorbed by higher operating costs while cash conversion weakens sharply.
From FY2023 to FY2025, revenue rose from$106.4B to$129.7B , yet operating margin fell from3.8% to2.1% , indicating that added scale did not translate into incremental operating profitability. Over the same period, SG&A increased from$13.2B to$15.5B while operating income declined from$4.0B to$2.7B , tying the margin pressure to a cost base that expanded faster than operating earnings.
Operating cash flow fell from
Assets rose from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Humana Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Humana Inc. has an operating margin of 2.1%, meaning the company retains $2 of operating profit per $100 of revenue. This results in a moderate score of 50/100, indicating healthy but not exceptional operating efficiency. This is down from 2.2% the prior year.
Humana Inc.'s revenue grew 10.1% year-over-year to $129.7B, a solid pace of expansion. This earns a growth score of 66/100.
Humana Inc. has elevated debt relative to equity (D/E of 0.70), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 27/100, reflecting increased financial risk.
Humana Inc.'s current ratio of 2.00 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.
Humana Inc. has a free cash flow margin of 0.3%, earning a moderate score of 30/100. The company generates positive cash flow after capital investments, but with room for improvement.
Humana Inc. earns a strong 6.7% return on equity (ROE), meaning it generates $7 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 69/100. This is down from 7.4% the prior year.
Humana Inc. scores 4.95, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Humana Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Humana Inc. generates $0.78 in operating cash flow ($921.0M OCF vs $1.2B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Humana Inc. earns $4.29 in operating income for every $1 of interest expense ($2.7B vs $631.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Humana Inc. generated $39.6B in revenue in Q1 2026. This represents an increase of 23.5% from the same quarter a year earlier. Against the prior quarter it is up 21.9%.
Humana Inc.'s EBITDA was $1.9B in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.7% from the same quarter a year earlier. Against the prior quarter it is up 397.7%.
Humana Inc. reported $1.2B in net income in Q1 2026. This represents a decrease of 4.7% from the same quarter a year earlier. Against the prior quarter it is up 249.0%.
Humana Inc. earned $9.83 per diluted share (EPS) in Q1 2026. This represents a decrease of 4.6% from the same quarter a year earlier. Against the prior quarter it is up 249.2%.
Cash & Balance Sheet
Humana Inc. generated $1.1B in free cash flow in Q1 2026, representing cash available after capex. This represents an increase of 380.1% from the same quarter a year earlier. Against the prior quarter it is up 161.1%.
Humana Inc. held $5.0B in cash against $12.3B in long-term debt as of Q1 2026.
Humana Inc. paid $0.89 per share in dividends in Q1 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Humana Inc.'s operating margin was 4.4% in Q1 2026, reflecting core business profitability. This is down 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.9 percentage points.
Humana Inc.'s net profit margin was 3.0% in Q1 2026, showing the share of revenue converted to profit. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.4 percentage points.
Humana Inc.'s ROE was 6.4% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.9 percentage points.
Not reported for Q1 2026.
Capital Allocation
Humana Inc. spent $107.0M on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 1088.9% from the same quarter a year earlier. Against the prior quarter it is up 154.8%.
Humana Inc. invested $121.0M in capex in Q1 2026, funding long-term assets and infrastructure. This represents an increase of 27.4% from the same quarter a year earlier. Against the prior quarter it is down 40.1%.
Not reported for Q1 2026.
HUM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.6B+23.5% | $32.5B+11.3% | $32.6B+11.1% | $32.4B+9.6% | $32.1B+8.4% | $29.2B+10.4% | $29.4B+11.3% | $29.5B+10.4% |
| SG&A Expenses | $4.0B+19.1% | $4.4B+6.5% | $4.1B+22.3% | $3.5B+12.7% | $3.4B+11.1% | $4.2B+8.9% | $3.3B+2.1% | $3.1B+1.2% |
| Operating Income | $1.8B-12.9% | -$808.0M-48.8% | $400.0M-45.1% | $1.1B-3.8% | $2.0B+62.9% | -$543.0M-56.0% | $728.0M-39.6% | $1.1B-20.5% |
| EBITDA | $1.9B-12.7% | -$644.0M-92.2% | $573.0M-38.9% | $1.3B-5.7% | $2.2B+52.0% | -$335.0M-127.9% | $938.0M-33.3% | $1.4B-16.8% |
| Interest Expense | $193.0M+20.6% | $146.0M-11.0% | $168.0M-0.6% | $157.0M-6.5% | $160.0M+0.6% | $164.0M+12.3% | $169.0M+48.2% | $168.0M+40.0% |
| Income Tax | $395.0M-2.7% | -$249.0M-15.3% | -$86.0M-155.5% | $179.0M-19.7% | $406.0M+61.8% | -$216.0M-188.0% | $155.0M-39.5% | $223.0M-24.7% |
| Net Income | $1.2B-4.7% | -$796.0M-14.9% | $195.0M-59.4% | $545.0M-19.7% | $1.2B+67.9% | -$693.0M-28.1% | $480.0M-42.3% | $679.0M-29.2% |
| EPS (Basic) | $9.85-4.5% | -$6.60-14.8% | $1.62-59.4% | $4.52-19.7% | $10.31+68.2% | -$5.75-34.3% | $3.99-40.8% | $5.63-26.9% |
| EPS (Diluted) | $9.83-4.6% | -$6.59-14.8% | $1.62-59.3% | $4.51-19.8% | $10.30+68.6% | -$5.74-34.7% | $3.98-40.7% | $5.62-26.6% |
| Diluted Shares (Avg) | 121M-0.2% | N/A | 121M0.0% | 121M+0.1% | 121M-0.3% | N/A | 121M-2.6% | 121M-3.6% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
HUM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $55.3B+8.5% | $48.9B+5.2% | $49.7B-0.6% | $50.4B+0.5% | $50.9B+1.7% | $46.5B-1.2% | $50.0B-10.6% | $50.1B-11.3% |
| Current Assets | $38.1B+10.6% | $32.7B+9.8% | $32.8B-0.5% | $33.6B+2.3% | $34.4B+5.0% | $29.8B-0.6% | $32.9B-13.9% | $32.9B-15.2% |
| Cash & Equivalents | $5.0B+16.5% | $4.2B+89.1% | $5.4B+5.3% | $4.0B-26.6% | $4.3B-28.1% | $2.2B-52.7% | $5.1B-66.2% | $5.5B-66.1% |
| Short-Term Investments | $17.0B-4.9% | $15.7B-13.8% | $16.7B-12.1% | $17.7B+1.4% | $17.9B+7.1% | $18.2B+9.6% | $19.0B+25.7% | $17.4B+14.2% |
| Long-Term Investments | $626.0M+52.7% | $493.0M+17.1% | $440.0M+10.0% | $431.0M+11.1% | $410.0M+7.9% | $421.0M+10.2% | $400.0M+8.1% | $388.0M-0.3% |
| Goodwill | $10.5B+8.9% | $9.7B+0.6% | $9.6B+0.3% | $9.6B+0.7% | $9.6B+0.7% | $9.6B+0.8% | $9.6B+0.5% | $9.6B+0.3% |
| Total Liabilities | $36.6B+10.6% | $31.2B+3.8% | $31.1B-3.8% | $32.1B-3.9% | $33.1B-2.3% | $30.0B-2.3% | $32.4B-16.8% | $33.4B-15.7% |
| Current Liabilities | $21.5B+19.2% | $16.3B-3.5% | $16.2B-13.6% | $17.2B-13.0% | $18.0B-8.4% | $16.9B-10.2% | $18.7B-32.7% | $19.8B-30.0% |
| Non-Current Liabilities | $15.1B+0.4% | $14.8B+13.2% | $15.0B+9.5% | $14.8B+9.3% | $15.1B+6.0% | $13.1B+10.3% | $13.7B+23.3% | $13.6B+20.3% |
| Long-Term Debt | $12.3B-3.6% | $12.4B+11.0% | $12.6B+6.1% | $12.6B+7.2% | $12.7B+2.7% | $11.1B+9.1% | $11.9B+25.3% | $11.7B+20.8% |
| Total Equity | $18.6B+4.7% | $17.7B+7.8% | $18.5B+5.4% | $18.2B+9.4% | $17.8B+10.0% | $16.4B+0.7% | $17.6B+3.6% | $16.7B-1.0% |
| Retained Earnings | $30.2B+2.4% | $29.1B+2.7% | $30.0B+3.0% | $29.9B+4.0% | $29.5B+4.5% | $28.3B+2.8% | $29.1B+3.3% | $28.7B+4.6% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
HUM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.3B+278.9% | -$1.7B-212.9% | $971.0M-47.7% | $1.3B+4.8% | $331.0M-21.7% | -$528.0M+92.6% | $1.9B+48.4% | $1.2B-61.8% |
| Depreciation & Amortization | $163.0M-10.9% | $164.0M-21.2% | $173.0M-17.6% | $178.0M-16.0% | $183.0M-12.4% | $208.0M+3.5% | $210.0M+4.5% | $212.0M+11.0% |
| Stock-Based Compensation | $51.0M+4.1% | N/A | N/A | N/A | $49.0M+8.9% | N/A | N/A | N/A |
| Capital Expenditures | $121.0M+27.4% | $202.0M+31.2% | $135.0M+3.8% | $114.0M0.0% | $95.0M-46.3% | $154.0M-45.6% | $130.0M-44.4% | $114.0M-56.8% |
| Free Cash Flow | $1.1B+380.1% | -$1.9B-171.8% | $836.0M-51.6% | $1.2B+5.3% | $236.0M-4.1% | -$682.0M+90.8% | $1.7B+69.7% | $1.1B-62.3% |
| Investing Cash Flow | -$2.6B-913.1% | $632.0M+1103.2% | $980.0M+166.5% | $347.0M+134.6% | $314.0M+175.8% | -$63.0M+92.9% | -$1.5B-151.8% | -$1.0B-36.7% |
| Financing Cash Flow | $2.0B+48.1% | -$168.0M+92.7% | -$603.0M+21.7% | -$1.8B-194.8% | $1.4B+14.7% | -$2.3B+5.5% | -$770.0M+55.6% | -$620.0M-1822.2% |
| Dividends Paid | $107.0M-0.9% | $109.0M+0.9% | $107.0M0.0% | $106.0M-0.9% | $108.0M-0.9% | $108.0M-2.7% | $107.0M-1.8% | $107.0M-3.6% |
| Share Buybacks | $107.0M+1088.9% | $42.0M-14.3% | $0-100.0% | $100.0M+104.1% | $9.0M-98.7% | $49.0M-91.4% | $2.0M-99.5% | $49.0M-90.7% |
HUM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 4.4%-1.9pp | -2.5%-0.6pp | 1.2%-1.3pp | 3.4%-0.5pp | 6.3%+2.1pp | -1.9%-0.5pp | 2.5%-2.1pp | 3.9%-1.5pp |
| Net Margin | 3.0%-0.9pp | -2.5%-0.1pp | 0.6%-1.0pp | 1.7%-0.6pp | 3.9%+1.4pp | -2.4%-0.3pp | 1.6%-1.5pp | 2.3%-1.3pp |
| Return on Equity | 6.4%-0.6pp | -4.5%-0.3pp | 1.1%-1.7pp | 3.0%-1.1pp | 7.0%+2.4pp | -4.2%-0.9pp | 2.7%-2.2pp | 4.1%-1.6pp |
| Return on Assets | 2.1%-0.3pp | -1.6%-0.1pp | 0.4%-0.6pp | 1.1%-0.3pp | 2.4%+1.0pp | -1.5%-0.3pp | 1.0%-0.5pp | 1.4%-0.3pp |
| Current Ratio | 1.77-0.1x | 2.00+0.2x | 2.02+0.3x | 1.95+0.3x | 1.91+0.2x | 1.76+0.2x | 1.76+0.4x | 1.66+0.3x |
| Debt-to-Equity | 0.66-0.1x | 0.700.0x | 0.680.0x | 0.690.0x | 0.72-0.1x | 0.68+0.1x | 0.68+0.1x | 0.70+0.1x |
| Asset Turnover | 0.72+0.1x | 0.660.0x | 0.66+0.1x | 0.64+0.1x | 0.630.0x | 0.63+0.1x | 0.59+0.1x | 0.59+0.1x |
| FCF Margin | 2.9%+2.1pp | -5.7%-3.4pp | 2.6%-3.3pp | 3.6%-0.1pp | 0.7%-0.1pp | -2.3%+25.7pp | 5.9%+2.0pp | 3.7%-7.2pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Humana Inc. HUM | FY2025 | $129.7B | $1.2B | 0.9% | $45.6B | 50/100 |
| Elevance Health, Inc. ELV | FY2025 | $199.1B | $5.7B | 2.8% | $84.3B | 49/100 |
| Centene Corporation CNC | FY2025 | $194.8B | -$6.7B | -3.4% | $30.7B | 36/100 |
| CVS Health Corporation CVS | FY2025 | $402.1B | $1.8B | 0.4% | $109.6B | 35/100 |
| The Cigna Group CI | FY2025 | $274.9B | $6.0B | 2.2% | $71.8B | 42/100 |
| Molina Healthcare, Inc. MOH | FY2025 | $45.4B | $472.0M | 1.0% | $9.9B | 63/100 |
Where Humana Inc. Ranks
Frequently Asked Questions
What is Humana Inc.'s annual revenue?
Humana Inc. (HUM) reported $129.7B in total revenue for fiscal year 2025. This represents a 10.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Humana Inc.'s revenue growing?
Humana Inc. (HUM) revenue grew by 10.1% year-over-year, from $117.8B to $129.7B in fiscal year 2025.
Is Humana Inc. profitable?
Yes, Humana Inc. (HUM) reported a net income of $1.2B in fiscal year 2025, with a net profit margin of 0.9%.
What is Humana Inc.'s EBITDA?
Humana Inc. (HUM) had EBITDA of $3.4B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Humana Inc. have?
As of fiscal year 2025, Humana Inc. (HUM) had $4.2B in cash and equivalents against $12.4B in long-term debt.
What is Humana Inc.'s operating margin?
Humana Inc. (HUM) had an operating margin of 2.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Humana Inc.'s net profit margin?
Humana Inc. (HUM) had a net profit margin of 0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Humana Inc. pay dividends?
Yes, Humana Inc. (HUM) paid $3.54 per share in dividends during fiscal year 2025.
What is Humana Inc.'s return on equity (ROE)?
Humana Inc. (HUM) has a return on equity of 6.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Humana Inc.'s free cash flow?
Humana Inc. (HUM) generated $375.0M in free cash flow during fiscal year 2025. This represents a -84.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Humana Inc.'s operating cash flow?
Humana Inc. (HUM) generated $921.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Humana Inc.'s total assets?
Humana Inc. (HUM) had $48.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Humana Inc.'s capital expenditures?
Humana Inc. (HUM) invested $546.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Humana Inc.'s current ratio?
Humana Inc. (HUM) had a current ratio of 2.00 as of fiscal year 2025, which is generally considered healthy.
What is Humana Inc.'s debt-to-equity ratio?
Humana Inc. (HUM) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Humana Inc.'s return on assets (ROA)?
Humana Inc. (HUM) had a return on assets of 2.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Humana Inc.'s P/E ratio?
Humana Inc. (HUM) trades at 40.3x earnings, its market capitalization divided by net income of $1.1B net income, trailing 12 months to March 31, 2026. The market capitalization is $45.6B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Humana Inc.'s price-to-sales ratio?
Humana Inc. (HUM) trades at 0.3x sales, its market capitalization divided by revenue of $137.2B revenue, trailing 12 months to March 31, 2026. The market capitalization is $45.6B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Humana Inc.'s Altman Z-Score?
Humana Inc. (HUM) has an Altman Z-Score of 4.95, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Humana Inc.'s Piotroski F-Score?
Humana Inc. (HUM) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Humana Inc.'s earnings high quality?
Humana Inc. (HUM) has an earnings quality ratio of 0.78x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Humana Inc. cover its interest payments?
Humana Inc. (HUM) has an interest coverage ratio of 4.29x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Humana Inc.?
Humana Inc. (HUM) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.